CRC 11120: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects with Advanced Solid Tumors
- Type of Study
- Cancer (Oncology) - Solid Tumor
- Location
- Swedish Cancer Institute
- Short Description
Purpose: This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm, dose-escalation (3+3) study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI0639
- Status
- Temporarily Closed
- Principal Investigator
- Philip Gold, M.D.
- Eligibility Notes
- Histologically or cytologically confirmed solid tumors that are refractory to standard therapy or for which no standard therapy exist
- ECOG Performance Status of 0 or 1
- Prior therapy against VEGF or VEGFRs including, but not limited to bevacizumab, sunitinib, sorafenib, pazopanib, motesanib (AMG706), or cediranib (AZD2171), is permitted so long as the agent does not have any known activity against DLL4 and the last dose received s at least 6 weeks prior to first dose of MEDI0639
- No concurrent or previous treatment with inhibitors of DLL4
- No concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment
- No tumors with squamous cell histology
- No known HIV positive or Hepatitis A, B, or C infection
- More Info Link
- Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
- Phone
- (206) 215-3086
- SwedishCancer@swedish.org
